An Open-label, Multicenter Study of the Pharmacokinetics, Efficacy and Safety of Olokizumab in Pediatric and Adolescent Patients With Active Juvenile Idiopathic Arthritis
Latest Information Update: 13 Apr 2026
At a glance
- Drugs Olokizumab (Primary)
- Indications Juvenile rheumatoid arthritis
- Focus Pharmacokinetics
- Sponsors R-Pharm
Most Recent Events
- 13 Apr 2026 New trial record